TNF Pharmaceuticals, Inc. (Nasdaq: TNFA) ("TNF" or the "Company"), a clinical stage biopharmaceutical company committed to ...

There have been new developments in treatments for chronic spontaneous urticaria, with dupilumab, remibrutinib, and barzolvolimab showing complete response in patients, particularly among those who ...

A new scientific breakthrough may soon offer hope for people affected by Alzheimer’s disease. A group of researchers in Spain ...

Key findings highlight the therapeutic potential of cytokine-targeted biologics, Janus kinase (JAK) inhibitors, and emerging strategies such as miRNA modulation and engineered cytokines. Autoimmunity ...